The Journal of Pediatrics
Volume 143, Issue 1 , Pages 16-25 , July 2003

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

Received 16 April 2002 ,Revised 28 January 2003 ,Accepted 25 March 2003.

References 

  1. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. 1974;1:1–5
  2. Demmler GJ. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis. 1991;13:315–329
  3. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997;130:624–630
  4. Harris S, Ahlfors K, Ivarsson S, Lernmark B, Svanberg L. Congenital cytomegalovirus infection and sensorineural hearing loss. Ear Hear. 1984;5:352–355
  5. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr. 1999;135:60–64
  6. McCracken GH, Shinefield HMR, Cobb K, Rausen AR, Dische R, Eichenwald HF. Congenital cytomegalic inclusion disease: a longitudinal study of 20 patients. Am J Dis Child. 1969;117:522–539
  7. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics. 1980;66:758–762
  8. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N Engl J Med. 1971;285:203–214
  9. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Engl J Med. 1962;266:1233–1244
  10. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT, et al.  the Houston Congenital CMV Longitudinal Study Group   Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr. 2001;138:325–331
  11. Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, Weaver TG. Symptomatic congenital cytomegalovirus: disorders of language, learning and hearing. Am J Dis Child. 1982;136:902–905
  12. Pass RF, Fowler KB, Boppana S. Clinical importance of cytomegalovirus infection: an overview. In:  Landini MP editors. Progress in Cytomegalovirus Research. New York: Elsevier Science Publishers; 1991;p. 3–10
  13. Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol. 2000;11:283–290
  14. Yow MD, Demmler GJ. Congenital cytomegalovirus disease: 20 years is long enough. N Engl J Med. 1992;326:702–703
  15. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al.  the NIAID Collaborative Antiviral Study Group   Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J Infect Dis. 1997;175:1080–1086
  16. Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, et al.  the NIAID Collaborative Antiviral Study Group   Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther. 1993;53:15–21
  17. Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, et al.  the NIAID Collaborative Antiviral Study Group   Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrob Agents Chemother. 1996;40:2202–2205
  18. Berg FS. Characteristics of the target population. In:  Berg FS,  Blair JC,  Viehweg SH, et al. editor. Educational audiology for the hard of hearing child. Orlando (FL): Grune and Stratton; 1986;
  19. Habilitation and rehabilitation. In:  Northern JL editors. Hearing disorders. Boston (MA): Little, Brown, and Company; 1976;
  20. Pediatric ACTG website. Tables for patients 0-3 months of age. Available at: http://pactg.s-3.com/members/pedtoxtb.htm. Toxicity tables for patients >3 months of age. Available at: http://pactg.s-3.com/members/babytox.htm toxicity. Last accessed February 28, 2002.
  21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22
  22. Clogg CC, Rubin DB, Schenker N, Schultz B, Weidman L. Multiple imputation of industry and occupation codes in census public-use samples using Bayesian Logistic Regression. J Am Stat Assoc. 1991;86:68–78
  23. SAS/STAT Users guide. Version 7-1. Vol. 3. Cary (NC): SAS Institute; 1999; p. 1368–87
  24. Davis H, Silverman SR. Hearing and Deafness. New York: Holt, Rinehart and Winston; 1970;
  25. Goetzinger CP. The Psychology of hearing impairment. In:  Katz J editors. Handbook of clinical audiology. Baltimore (MD): Williams and Wilkins; 1972;
  26. High WS, Fairbanks G, Glorig A. Scale for self-assessment of hearing handicap. J Speech Hear Disord. 1964;29:3
  27. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J. 1992;11:93–99
  28. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day care centers. N Engl J Med. 1986;314:1414–1418
  29. Adler SP. Molecular epidemiology of cytomegalovirus: evidence for viral transmission to parents from children infected at a day care center. Pediatr Infect Dis J. 1986;5:315–318
  30. Adler SP. Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day care center, their parents, and caretakers. J Pediatr. 1988;112:366–372
  31. Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980–1990. J Infect Dis. 1993;168:552–556
  32. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr. 1994;124:318–322
  33. Ganciclovir package insert, Hoffman-La Roche, Inc.

☆ Supported under contract with the Virology Branch, Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), NO1-AI-15113 and NO1-AI-62554, and by grants from the General Clinical Research Center Program (RR-032) and the State of Alabama.Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada; 2000; Abstract 1942. Recipient of the ICAAC Program Committee Award in the area of Therapy of Microbial Diseases.

PII: S0022-3476(03)00192-6

doi: 10.1016/S0022-3476(03)00192-6

The Journal of Pediatrics
Volume 143, Issue 1 , Pages 16-25 , July 2003

Article Tools